In Veranova Bidco LP v Johnson Matthey Plc & Ors ([2026] EWHC 1021 (Comm)), the Commercial Court considered whether the sellers of a pharmaceutical business were in fraudulent breach of certain warranties given in an SPA. The judgment is a salutary reminder of the high threshold for proving fraudulent breach.
Of particular interest was an unsuccessful attempt by the Claimant to base the fraud claim on an aggregation of knowledge held by various different individuals at the Defendant. The claim failed and the Court held that, for fraud to be established against a company, a single executive had to:
The dispute arose from the sale of the Defendant’s “Health Business”, a global manufacturer of buprenorphine hydrochloride (“BHCL”), which is used to treat opioid addiction. Its largest customer for BHCL was Alvogen, which purchased it under a long-term supply contract. The contract included a “price match clause”, which could be invoked once a year if Alvogen found a lower price elsewhere and essentially enabled Alvogen to buy the BHCL elsewhere if the Health Business did not match the price. In October 2021, Alvogen had invoked the price match clause, having received an offer to supply BHCL at around $8 per gram (the “Olesen Offer”) — roughly half the price then charged by the Health Business.
Under a Sale and Purchase Agreement (“SPA”) signed on 16 December 2021, the Claimant agreed to purchase the Health Business. The SPA contained the following warranties, which were subject to a typical disclosure regime, including a detailed Disclosure Letter and incorporation of various data room materials:
However, the SPA heavily restricted the sellers’ warranty liability where the buyer had taken out warranty and indemnity insurance, save where a claim was based on fraud or wilful misconduct.
The Claimant accepted that it had been informed during the sale process that the Health Business was renegotiating the price of BHCL charged to Alvogen, but claimed it had been given the false impression that those negotiations related to a smaller reduction, from $16/g to $12-13/g, rather than the actual reduction to around $8/g. Upon learning about the offer, the claimant issued proceedings for fraudulent breach of warranty.
In relation to the “Ordinary and Usual Course” warranty, the Claimant submitted that the negotiations following the Olesen Offer amounted to a material alteration to the nature, scope or manner of the business. The Judge disagreed, holding that pricing negotiations were entirely to be expected in the ordinary course of a long-term supply relationship, particularly for a business where price erosion was a feature of the commercial landscape and where the price match clause had been triggered before. The warranty was directed at the nature, scope and manner of the business, not of particular contracts.
On the “Key Contracts” warranty, it was common ground that the agreement with Alvogen was a key contract and that the price was a material term for the purposes of this warranty. The court found that the invocation by Alvogen of the price match clause in October 2021 in respect of the Olesen Offer marked the initiation of renegotiations within the meaning of this warranty. The court was satisfied that, as at 16 December 2021 (when the SPA was signed), the conclusion of negotiations would have an adverse and detrimental effect on the Health Business, irrespective of whether the precise financial impact could be finally quantified. Thus the “Key Contracts” warranty (i.e. that none of the companies was “currently renegotiating any material term of any Key Contract, which upon conclusion, would have an adverse or detrimental effect on the Businesses") was false.
Having found the “Key Contracts” warranty to be false, the court turned to whether there had been fair disclosure. The SPA defined “Disclosed” as “fairly disclosed with sufficient detail to allow a reasonable buyer to make an informed assessment of the nature and scope of the matter concerned”.
The Disclosure Letter had included statements that:
Mrs Justice Dias accepted that this put the Claimant on notice that there were pricing pressure and discussions with Alvogen. However, she held that fair disclosure required more once the Olesen offer had been verified as bona fide. A general reference to “increased competition” and “ongoing” pricing discussions was not sufficient. The Defendant should have disclosed the following and was therefore in breach of warranty:
Whilst there was a breach of warranty, the limitations in the SPA meant that the Claimant needed to prove fraud on the part of the Defendants. This was the central battleground between the parties.
The Claimant argued that it was sufficient if one person within Johnson Matthey knew the warranty was false and another person signed or allowed the warranty to be given. In other words, knowledge of the relevant facts and of the warranties could and should be “aggregated” across different individuals within the corporate seller.
The Judge disagreed. Drawing on various authorities, Mrs Justice Dias reaffirmed that:
The Judge held that none of the Defendant’s executives on their own had the requisite knowledge of all of the above, and the fraud claim accordingly failed. Of further note were the following points:
The court acknowledged that the Claimant was entitled to feel aggrieved that the Olesen Offer was not adequately disclosed. However, the terms of the SPA expressly precluded a claim in negligence or for breach of contract where there was insurance — and those were the terms (and allocation of risk) to which the Claimant had agreed.
Whilst it does not make new law, Veranova v Johnson Matthey will be a welcome decision to company directors and executives (and their lawyers), confirming as it does that claimants will not be permitted to seek to construct allegations of fraud based on snippets of knowledge held by various individuals. Were it otherwise, companies would run the serious risk in any transaction that knowledge held by different individuals could be pieced together and deployed later.
Veranova v Johnson Matthey underscores that where an SPA confines the path to liability to fraud alone, a claimant will almost inevitably be left without a remedy unless its evidence of fraud is compelling. In particular, where the defendant is a company, the dishonesty must be attributable to single, controlling mind. Any such claim is inherently high-risk if the evidence is not watertight.
The case is also notable for the court’s pointed criticism of the Claimant’s conduct of the case. Allegations of fraud carry serious reputational consequences, and this judgment illustrates that the manner in which such a claim is pursued will itself attract scrutiny. Claimants would do well to ensure their case is presented fairly and proportionately.
